10-Q: Invivyd Reports First Revenue Following PEMGARDA EUA, Faces Going Concern Uncertainty

Invivyd, Inc. reports its first product revenue following emergency use authorization for PEMGARDA, while also disclosing substantial doubt about its ability to continue as a going concern.

Summary

• Invivyd, Inc., a biopharmaceutical company, reported its first product revenue of $2.3 million from sales of PEMGARDA after receiving emergency use authorization (EUA) in March 2024.
• The company incurred a net loss of $90.7 million for the six months ended June 30, 2024, and has an accumulated deficit of $822.8 million.
• Research and development expenses decreased to $61.5 million for the six months ended June 30, 2024, compared to $70.8 million for the same period in 2023.
• Selling, general, and administrative expenses increased to $36.0 million for the six months ended June 30, 2024, compared to $21.2 million for the same period in 2023.
• The company has concluded that there is substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations beyond one year from the issuance of the financial statements.
• Invivyd is dependent on third-party organizations for manufacturing and processing its product candidates, and relies on a single contract manufacturer.
• The company is also dependent on a limited number of third parties that provide license rights used in the development and commercialization of its product candidates.
• As of June 30, 2024, the company had $147.9 million in cash and cash equivalents.
• The company has noncancelable purchase obligations of $52.6 million for commercial drug substance and drug product manufacturing, and $24.7 million for procurement of materials.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company has achieved a significant milestone with the EUA and first revenue for PEMGARDA, the substantial doubt about its ability to continue as a going concern and the significant losses raise serious concerns. The reliance on third parties and the high expenses also contribute to a negative outlook.

Positives

• The company successfully launched PEMGARDA and generated its first product revenue.
• The company has a repeatable immunobridging pathway to future potential EUAs for serial, novel mAbs for the prevention and treatment of symptomatic COVID-19.
• The company nominated VYD2311 as a drug candidate, which is expected to be the next pipeline program to advance into clinical development.

Negatives

• The company has incurred significant losses and negative cash flows from operations since its inception.
• The company has substantial doubt about its ability to continue as a going concern.
• The company is dependent on a single third-party contract manufacturer.
• The company is dependent on a limited number of third parties that provide license rights.
• The company has significant noncancelable purchase obligations.

Risks

• The company may not be able to obtain additional funding on acceptable terms, or at all.
• The company may be forced to delay, reduce, or eliminate some or all of its research and development programs if it cannot obtain sufficient capital.
• The company's research and development programs could be adversely affected by a significant interruption in the supply of necessary materials.
• The company could experience delays in the development and commercialization of its product candidates if license agreements are terminated.
• The company is subject to risks associated with market acceptance and commercialization of products, competition from other products, and compliance with government regulations.

Future Outlook

The company anticipates leveraging its INVYMAB platform to periodically introduce new or engineered mAb candidates as the SARS-CoV-2 virus evolves. The company expects VYD2311 to be the next pipeline program to advance into clinical development. The company also expects to apply its INVYMAB platform approach to produce lead molecules for other viral diseases, such as influenza.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on developing monoclonal antibodies for infectious diseases, particularly COVID-19, aligns with the ongoing global health concerns and the need for effective prevention and treatment options.

Comparison to Industry Standards

• The company's reliance on a single contract manufacturer is a common practice for smaller biopharmaceutical companies, but it introduces supply chain risks.
• The company's high R&D spending is typical for companies in the early stages of drug development, but the need for additional funding and the going concern warning are concerning.
• The company's commercialization of PEMGARDA is a positive step, but the long-term success will depend on market acceptance and competition from other treatments.
• The company's approach to developing a continuous repertoire of SARS-CoV-2 neutralizing mAbs is similar to the approach used for influenza vaccines, which is a novel approach in the COVID-19 space.
• The company's reliance on immunobridging pathways for future EUAs is a strategy to expedite the development and approval process, which is a common practice in the industry.

Management Changes

Legal Proceedings

• A securities class action lawsuit, Brill v. Invivyd, Inc., et. al., is ongoing, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 concerning statements about ADG20's effectiveness against the Omicron variant of COVID-19.

Related Party Transactions

• The company has ongoing transactions with Adimab under various agreements, including the Adimab Assignment Agreement, the Adimab Collaboration Agreement, and the Adimab Platform Transfer Agreement.
• The company had transactions with Population Health Partners, L.P. (PHP), where Tamsin Berry, a member of the company's board of directors, is a Limited Partner.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding and the going concern warning.
• Employees may experience uncertainty about their job security due to the company's financial challenges.
• Customers may be impacted by potential delays or disruptions in the supply of PEMGARDA due to the company's reliance on a single contract manufacturer.
• Suppliers and creditors face the risk of non-payment or delayed payments due to the company's financial difficulties.

Next Steps

• The company will continue to support the commercialization of PEMGARDA.
• The company will establish streamlined development pathways for new mAb candidates.
• The company will pursue a potential EUA for COVID-19 treatment in certain immunocompromised people.
• The company will advance VYD2311 through clinical development.
• The company will continue to discover and develop additional product candidates.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibodies, biopharmaceutical, emergency use authorization, immunocompromised, research and development, manufacturing, going concern, financial results